Palvella Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Palvella Therapeutics, Inc. (PVLA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-03-31
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2017-09-30 was 0.00%.
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2017-06-30 was 0.00%.
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2017-03-31 was 0.00%.
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2016-09-30 was 0.00%.
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2025 was 0.00%.
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2017 was 0.00%.
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2016 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|
| 2025-12-31 | 0.00% 10-K · filed 2026-03-31 | |||
| 2024-12-31 | 0.00% 10-K · filed 2025-03-31 | |||
| 2017-12-31 | 0.00% 10-K · filed 2018-03-15 | |||
| 2017-09-30 | 0.00% 10-Q · filed 2017-11-13 | 0.00% 10-Q · filed 2017-11-13 | ||
| 2017-06-30 | 0.00% 10-Q · filed 2017-08-11 | 0.00% 10-Q · filed 2017-08-11 | ||
| 2017-03-31 | 0.00% 10-Q · filed 2017-05-15 | |||
| 2016-12-31 | 0.00% 10-K · filed 2018-03-15 | |||
| 2016-09-30 | 0.00% 10-Q · filed 2017-11-13 | 0.00% 10-Q · filed 2017-11-13 | ||
| 2016-06-30 | 0.00% 10-Q · filed 2017-08-11 | 0.00% 10-Q · filed 2017-08-11 | ||
| 2016-03-31 | 0.00% 10-Q · filed 2017-05-15 | |||
| 2015-12-31 | 0.00% 10-K · filed 2017-03-30 | |||
| 2015-09-30 | 0.00% 10-Q · filed 2016-11-10 | 0.00% 10-Q · filed 2016-11-10 | ||
| 2015-06-30 | 0.00% 10-Q · filed 2016-08-11 | 0.00% 10-Q · filed 2016-08-11 | ||
| 2015-03-31 | 0.00% 10-Q · filed 2016-05-12 | |||
| 2014-12-31 | 0.00% 10-K · filed 2016-03-23 | |||
| 2014-09-30 | 0.00% 10-Q · filed 2015-11-13 | 0.00% 10-Q · filed 2015-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |